Vis enkel innførsel

dc.contributor.authorTorkildsen, Øivinden_US
dc.contributor.authorMyhr, Kjell-Mortenen_US
dc.contributor.authorBø, Larsen_US
dc.date.accessioned2016-04-12T10:36:39Z
dc.date.available2016-04-12T10:36:39Z
dc.date.issued2015-11-13
dc.PublishedEuropean Journal of Neurology 2015, 23:18-27eng
dc.identifier.issn1468-1331
dc.identifier.urihttps://hdl.handle.net/1956/11895
dc.description.abstractBackground and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing remitting MS (RRMS). Methods: A literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015. Results: In this review the mode of action, documented treatment effects and side effects of the approved MS therapies are briefly discussed. Conclusions: Based on current knowledge of risk benefit of the approved MS medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first-line preparations for de novo RRMS. In the case of breakthrough disease on first-line therapy, or rapidly evolving severe RRMS, second-line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk benefit stratification.en_US
dc.language.isoengeng
dc.publisherWileyeng
dc.rightsAttribution CC BY-NC-NDeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/eng
dc.subjectdisease-modifyingeng
dc.subjectMultiple sclerosiseng
dc.subjectrevieweng
dc.subjectTreatmenteng
dc.titleDisease-modifying treatments for multiple sclerosis – a review of approved medicationsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2016-03-08T11:15:31Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2015 the authors
dc.identifier.doihttps://doi.org/10.1111/ene.12883
dc.identifier.cristin1339176


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC-ND